229 related articles for article (PubMed ID: 32143573)
21. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
22. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
[TBL] [Abstract][Full Text] [Related]
23. Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion.
Steurer S; Schwemmer L; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Luebke AM; Simon R; Sauter G; Izbicki J; Schroeder C; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Minner S; Meiners J
Oncotarget; 2019 Dec; 10(67):7096-7111. PubMed ID: 31903168
[TBL] [Abstract][Full Text] [Related]
24. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K; Ospina-Klinck D; Tsourlakis MC; Koop C; Wilczak W; Adam M; Simon R; Sauter G; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Prostate; 2014 Jul; 74(10):1012-22. PubMed ID: 24789172
[TBL] [Abstract][Full Text] [Related]
25. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
26. ERG rearrangement is present in a subset of transition zone prostatic tumors.
Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
Schroeder C; Grell J; Hube-Magg C; Kluth M; Lang D; Simon R; Höflmayer D; Minner S; Burandt E; Clauditz TS; Büscheck F; Jacobsen F; Huland H; Graefen M; Schlomm T; Sauter G; Steurer S
BMC Cancer; 2019 Mar; 19(1):193. PubMed ID: 30823906
[TBL] [Abstract][Full Text] [Related]
29. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
30. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
31. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.
Kind S; Kluth M; Hube-Magg C; Möller K; Makrypidi-Fraune G; Lutz F; Lennartz M; Rico SD; Schlomm T; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Lübke AM; Simon R; Sauter G; Marx A; Polonski A
Biomed Res Int; 2020; 2020():5845374. PubMed ID: 33195694
[TBL] [Abstract][Full Text] [Related]
32. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
Kind S; Büscheck F; Höflmayer D; Hube-Magg C; Kluth M; Tsourlakis MC; Steurer S; Clauditz TS; Luebke AM; Burandt E; Wilczak W; Hinsch A; Dum D; Weidemann S; Fraune C; Beyer B; Steuber T; Huland H; Graefen M; Fisch M; Simon R; Sauter G; Schlomm T; Minner S; Eichenauer T
World J Urol; 2020 Sep; 38(9):2185-2196. PubMed ID: 31745645
[TBL] [Abstract][Full Text] [Related]
33. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
34. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
35. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.
Minner S; Hager D; Steurer S; Höflmayer D; Tsourlakis MC; Möller-Koop C; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Sauter G; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Izbicki J; Burandt E; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Heumann A
Neoplasia; 2019 Sep; 21(9):872-881. PubMed ID: 31382165
[TBL] [Abstract][Full Text] [Related]
36. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
37. HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Burdelski C; Ruge OM; Melling N; Koop C; Simon R; Steurer S; Sauter G; Kluth M; Hube-Magg C; Minner S; Wittmer C; Wilczak W; Hinsch A; Lebok P; Izbicki JR; Heinzer H; Graefen M; Huland H; Schlomm T; Krech T
Exp Mol Pathol; 2015 Jun; 98(3):419-26. PubMed ID: 25794974
[TBL] [Abstract][Full Text] [Related]
38. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
40. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Kluth M; Hesse J; Heinl A; Krohn A; Steurer S; Sirma H; Simon R; Mayer PS; Schumacher U; Grupp K; Izbicki JR; Pantel K; Dikomey E; Korbel JO; Plass C; Sauter G; Schlomm T; Minner S
Mod Pathol; 2013 Jul; 26(7):975-83. PubMed ID: 23370768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
